How do I subscribe to ongoing alerts?

Subscribe to /feed/company/azienda-socio-sanitaria-territoriale-degli-spedali-civili-di-brescia.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia pipeline: 3 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 4 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
TAFLUPROST 0.0015% EYEDROPS	TAFLUPROST 0.0015% EYEDROPS	marketed
Latanoprost, Dorzolamide	Latanoprost, Dorzolamide	marketed	Prostaglandin analog + Carbonic anhydrase inhibitor combination	Prostaglandin F receptor (FP receptor) and Carbonic anhydrase II	Ophthalmology
LATANOPROST 0.005% EYEDROPS	LATANOPROST 0.005% EYEDROPS	marketed
Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin	Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin	phase 3			Oral Health
RASS inhibitors and/or RAS blockers	RASS inhibitors and/or RAS blockers	phase 3	RASS inhibitor / RAS blocker (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist)	Renin-angiotensin-aldosterone system components (ACE, angiotensin II receptor type 1, renin, or aldosterone receptor)	Cardiovascular
Cisplatin plus Etoposide	Cisplatin plus Etoposide	phase 3	Chemotherapy combination (platinum agent + topoisomerase II inhibitor)	DNA (cisplatin: alkylating agent); Topoisomerase II (etoposide)	Oncology
Betaine taurine PVP gel	Betaine taurine PVP gel	phase 3	Topical wound healing agent		Dermatology / Wound Care

Therapeutic area mix

Cardiovascular · 1
Dermatology / Wound Care · 1
Oncology · 1
Ophthalmology · 1
Oral Health · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Chiesi Farmaceutici S.p.A. · 1 shared drug class
European Lung Cancer Working Party · 1 shared drug class
Oneness Biotech Co., Ltd. · 1 shared drug class
Skingenix, Inc. · 1 shared drug class
Suez Canal University · 1 shared drug class
The Metis Foundation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia:

Cite this brief

Drug Landscape (2026). Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-socio-sanitaria-territoriale-degli-spedali-civili-di-brescia. Accessed 2026-05-17.